Antimitochindrial and antinuclear antibodies in primary biliary cholangitis

Primary sclerosing cholangitis and primary biliary cirrhosis.

Preview Although primary sclerosing cholangitis occurs most often in middle-aged or younger men and primary biliary cirrhosis in middle-aged or older women, the diseases have some traits in common-unfortunate ones. In both diseases, the cause is unknown, and liver transplantation is the only known effective therapy for advanced cases. Dr Fennerty discusses trials of medical treatments used in a...

Concurrence of multiple sclerosis and primary biliary cholangitis: A case series study

Obeticholic Acid in Primary Biliary Cholangitis.

In a double-blind, randomized, placebo-controlled study including 217 patients with primary biliary cholangitis, the authors show that obeticholic acid (a potent farnesoid X agonist) administered with ursodeoxycholic acid or as monotherapy significantly decreases serum alkaline phosphatase and bilirubin when compared to placebo. Pruritus (and serious adverse effects) was observed more frequentl...

Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.

BACKGROUND Antinuclear antibodies (ANA) giving a rim-like/membranous (RL/M) or a multiple nuclear dot (MND) pattern are highly specific for primary biliary cirrhosis (PBC). Aim and SUBJECTS To assess the prevalence of PBC specific ANAs, their Ig isotype, and their clinical significance in 90 PBC patients from Greece and Spain. Twenty eight patients with chronic hepatitis C, 23 patients with s...

Extrahepatic Manifestations of Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by progressive destruction of the intrahepatic bile ducts, leading to cholestasis. PBC is known to have both hepatic and extrahepatic manifestations. Extrahepatic manifestations are seen in up to 73% of patients with PBC, with the most common being Sjogren's syndrome, thyroid dysfunction and systemic sclerosis. It is...